| Lu, Haijie |
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 214 | RoW | Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin | Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University | Nasopharyngeal Carcinoma, Nutritional Support | 07/25 | 09/25 | | |
| Huang, Jianli |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 214 | RoW | Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin | Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University | Nasopharyngeal Carcinoma, Nutritional Support | 07/25 | 09/25 | | |
| Shi, Feifeng |
NCT06276309: Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors |
|
|
| Recruiting | N/A | 300 | RoW | | Fujian Maternity and Child Health Hospital | Neuroendocrine Neoplasm, China, Women, Cervical Cancer, Cervical Lesion | 12/24 | 02/25 | | |
NCT05475756: Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis |
|
|
| Recruiting | N/A | 264 | RoW | Intrauterine Biological Barrier, Intrauterine Adhesion Barrier Gel | Beijing Tiantan Hospital, Zhangzhou Municipal Hospital of Fujian Province, Guangzhou First People's Hospital, Tang-Du Hospital, Suzhou Municipal Hospital, Anhui Provincial Hospital | Intrauterine Adhesion | 05/24 | 05/25 | | |
NCT05051852: HPV Viral Load in Predicting the Prognosis of LSIL |
|
|
| Recruiting | N/A | 1000 | RoW | Follow up | Fujian Maternity and Child Health Hospital | HPV Infection, LSIL, Low-Grade Squamous Intraepithelial Lesions, Viral Load | 12/24 | 12/24 | | |
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China |
|
|
| Recruiting | N/A | 300 | RoW | Follow up | Fujian Maternity and Child Health Hospital | Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions | 12/25 | 05/26 | | |
NCT05282745: A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL |
|
|
| Recruiting | N/A | 4000 | RoW | Follow-up | Fujian Maternity and Child Health Hospital | HPV Infection, HSIL, High-Grade Squamous Intraepithelial Lesions, Viral Load | 12/24 | 12/24 | | |
NCT05283239: Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection |
|
|
| Recruiting | N/A | 1000 | RoW | Follow up | Fujian Maternity and Child Health Hospital | HPV Infection, LSIL, Low-Grade Squamous Intraepithelial Lesions, HSIL, High-Grade Squamous Intraepithelial Lesions, Virus Integration | 11/24 | 12/24 | | |
| Chen, Yu-Feng |
NCT06761027: mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 29 | RoW | Anlotinib combined with Sintilimab | Fujian Provincial Hospital | Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | 03/27 | 05/27 | | |
| Recruiting | N/A | 20 | RoW | | Fujian Provincial Hospital | Resectable Hepatocellular Carcinoma | 02/26 | 12/26 | | |
NCT06602011: Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) |
|
|
| Recruiting | N/A | 20 | RoW | TACE, Lenvatinib, combined with Tislelizumab group | Fujian Provincial Hospital | Hepatocellular Carcinoma | 07/27 | 10/28 | | |
